×
About 2,978 results

ECOG-ACRIN Guideline for Contouring and Treatment of Early Stage Anal Cancer Using IMRT...
https://doi.org/10.1016/j.prro.2022.01.015
Practical Radiation Oncology; Damico N, Meyer J et. al.

Jun 19th, 2022 - Previous anal cancer guidelines delineate target volumes similarly for all patients with squamous cell carcinoma of the anal canal and/or perianal skin (SCCA), regardless of disease stage. The purpose of this guideline is to provide customized radiation treatment recommendations for early stage (T1-2 N0 M0) anal cancer treated with intensity modulated and image guided radiation therapy (RT). A ...

Management of Postmenopausal Osteoporosis: ACOG Clinical Practice Guideline No. 2.
https://doi.org/10.1097/AOG.0000000000004730 10.7326/M19-0533 10.1359/jbmr.061113 10.1097/AOG.0000000000004514 10.1097/AOG.0000000000004519 10.1136/bmj.39489.470347.AD 10.1016/j.jclinepi.2010.04.026 10.1016/j.jclinepi.2014.12.011 10.1001/jama.285.3.320 10.1210/jc.2019-00221 10.1001/archinte.163.17.2052 10.1089/jwh.2012.3812 10.1007/s11606-009-1031-8 10.1016/j.amjmed.2017.02.042 10.1111/jgs.16455 10.1097/AOG.0000000000002459 10.1177/0002764213487340 10.1146/annurev-publhealth-040218-043750 10.1007/s11606-007-0217-1 10.4158/GL-2020-0524SUPPL 10.1007/s00198-014-2794-2 10.6004/jnccn.2013.0215 10.1097/GME.0000000000000515 10.1007/s10549-019-05464-w 10.1200/JCO.19.01696 10.1001/jama.2018.6537 10.1001/jama.2018.7498 10.1210/jc.2019-00192 10.1016/j.bone.2019.115081 10.26355/eurrev_201903_17414 10.1210/clinem/dgaa048 10.1016/j.ijsu.2019.03.004 10.1016/j.maturitas.2019.08.003 10.1210/jc.2019-00193 10.4158/EP161678.RA 10.1016/j.bone.2013.09.023 10.1016/j.bonr.2020.100729 10.1056/NEJMoa1808082 10.1007/s00198-007-0493-y 10.1016/j.clinthera.2019.05.001 10.1007/s00198-009-0930-1 10.1002/jbmr.2708 10.1016/j.jacr.2017.02.018 10.1515/hmbci-2019-0021 10.1056/NEJMoa1916525 10.1001/jama.296.24.2927 10.1002/jbmr.1494 10.1016/S2213-8587(17)30138-9 10.11622/smedj.2019028 10.1210/jc.2018-01965 10.1002/jbmr.3337 10.1359/JBMR.050509 10.1001/jama.2019.5780 10.1097/GME.0000000000000619 10.1097/01.AOG.0000441353.20693.78 10.1001/jama.290.13.1729 10.1359/jbmr.060312 10.1097/01.gme.0000123641.76105.b5 10.1016/j.fertnstert.2009.02.093 10.1210/jc.2013-1707 10.1016/s0002-9343(00)00490-3 10.1016/j.bone.2018.10.015 10.1007/s11657-019-0564-7 10.1210/jc.2018-00163 10.1056/NEJMoa1607948 10.1080/13697137.2018.1433655 10.1056/NEJMoa1708322 10.1002/jbmr.3452 10.1007/s00198-019-05146-9 10.1210/jc.2003-030501 10.1007/s00198-018-4759-3 10.1007/s00198-018-4704-5 10.1007/s00198-015-3386-5 10.1007/s00198-016-3699-z 10.1001/jamanetworkopen.2019.17789 10.1001/jama.2017.21640 10.1097/gme.0b013e31821fc8e0 10.1080/13697137.2016.1238451 10.3945/ajcn.116.151464 10.1097/GME.0b013e3182896ae5 10.3945/jn.115.219238 10.1007/s00198-011-1577-2 10.1080/08952841.2018.1418822 10.3390/nu10010097 10.1097/GME.0000000000001831 10.1007/s11657-013-0167-7
Obstetrics and Gynecology;

May 21st, 2022 - To provide updated evidence-based recommendations for the treatment of postmenopausal osteoporosis. Postmenopausal patients with primary osteoporosis. This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecology appointed by the ACOG Committee on Clinical Practice Guidelines-Gynecology and one external subj...

ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate ...
https://doi.org/10.1097/COC.0000000000000915
American Journal of Clinical Oncology; Bittner NHJ, Cox BW et. al.

May 20th, 2022 - The American College of Radiology (ACR), American Brachytherapy Society (ABS), and American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for transperineal permanent brachytherapy of prostate cancer. Transperineal permanent brachytherapy of prostate cancer is the interstitial implantation of low-dose rate radioactive seeds into the prostate gland...

Headaches in Pregnancy and Postpartum: ACOG Clinical Practice Guideline No. 3.
https://doi.org/10.1097/AOG.0000000000004766 10.1148/rg.2016150187 10.1016/S1474-4422(18)30322-3 10.1016/S0140-6736(20)30925-9 10.1186/s10194-020-01208-0 10.1212/01.wnl.0000252808.97649.21 10.1111/head.12150 10.1097/AOG.0000000000004519 10.1136/bmj.39489.470347 10.1016/j.jclinepi.2010.04.026 10.1016/j.jclinepi.2014.12.011 10.1177/0333102417738202 10.1152/physrev.00034.2015 10.1111/j.1526-4610.2006.00483.x 10.1007/s40265-018-0865-y 10.1212/wnl.25.3.239 10.1212/01.wnl.0000130338.62037.cc 10.1007/s10072-019-03792-9 10.1097/OGX.0000000000000738 10.1111/j.1468-2982.2008.01704.x 10.1111/j.1468-2982.2009.01935.x 10.11607/ofph.1869 10.1136/bmj.k80 10.1097/OGX.0000000000000540 10.1586/14737175.8.3.385 10.1111/ncn3.12322 10.1111/j.1526-4610.2009.01438.x 10.1097/NRL.0b013e3181663555 10.1097/AOG.0000000000004247 10.3390/ijerph18041503 10.1136/acupmed-2013-010480 10.4103/0973-7847.79105 10.1016/j.ejogrb.2019.07.021 10.1111/j.1526-4610.2011.02066.x 10.1186/s10194-017-0823-1 10.1007/s00415-018-8924-6 10.5505/agri.2018.85688 10.1016/j.emc.2016.06.014 10.1111/j.1468-1331.2011.03629.x 10.1111/j.1468-1331.2011.03562.x 10.1136/practneurol-2013-000664 10.1016/j.ajog.2007.01.034 10.1097/MAJ.0b013e31821e0e91 10.1111/head.13279 10.1007/s11910-019-0944-9 10.12891/ceog17052014 10.1111/j.1526-4610.2005.05012.x 10.3174/ajnr.A0506 10.1016/j.jacr.2019.05.030 10.1016/j.ncl.2019.09.001 10.1007/s11916-016-0585-5 10.5505/tbdhd.2014.74046 10.1001/jama.2016.12126 10.1097/AOG.0000000000002355 10.1016/j.ogc.2020.11.007 10.1161/STR.0000000000000211 10.1038/nrneurol.2009.100 10.1097/AOG.0000000000003891 10.1016/S1474-4422(12)70306-X 10.1016/j.ajog.2013.02.015 10.1136/bcr-2014-207332 10.1055/s-0037-1608940 10.1111/jog.12788 10.1016/S1474-4422(15)00111-8 10.1016/j.jogoh.2019.03.019 10.1007/s11739-017-1712-y 10.5530/jcdr.2016.2.7 10.1055/s-0038-1673681 10.1097/01.anes.0000282103.70955.c4 10.1111/j.1365-2044.2007.05285.x 10.1016/j.mpaic.2013.05.003 10.1213/ane.0000000000004336 10.1016/j.ijoa.2016.06.005 10.1016/j.jclinane.2011.04.003 10.1111/j.1399-6576.2005.00720.x 10.1007/s11845-019-02139-9 10.1213/ANE.0000000000004561 10.1016/j.mpaic.2019.06.003 10.1213/ane.0b013e3182501c06 10.1001/jamaneurol.2019.2995 10.1097/AAP.0000000000000455 10.1016/j.clineuro.2015.01.028 10.1016/j.jclinane.2014.07.008 10.1016/j.bja.2021.05.020 10.1111/anae.15491 10.1007/s11916-007-0024-8 10.1016/j.ajog.2006.09.044 10.1515/crpm-2015-0103 10.1097/NRL.0b013e318247bb59 10.1038/nrneurol.2009.114 10.1111/j.1526-4610.2011.01881.x 10.1007/s40618-014-0095-4 10.1530/EDM-14-0043 10.1177/1753495X15598917 10.1056/NEJMicm0900500 10.1136/bcr-2015-210198 10.1097/WNQ.0b013e31822df85a 10.1515/crpm-2019-0049 10.1056/NEJMcpc1501763 10.1213/01.ANE.0000072704.87018 10.1055/s-0038-1646952 10.1111/ppe.12595 10.3399/bjgp13X670895 10.1097/AOG.0b013e3181eeb2a1 10.1212/01.wnl.0000335946.53860.1d 10.1592/phco.22.12.1029.33595 10.1111/j.1468-2982.2004.00691.x 10.1046/j.1526-4610.2001.01189.x 10.1111/j.1526-4610.2011.02039.x 10.1016/j.ncl.2008.11.008 10.1046/j.1526-4610.1998.3807516.x 10.1016/j.pain.2014.08.009 10.1111/head.12208 10.1111/head.12203 10.1345/aph.1K176 10.1097/AOG.0000000000002235 10.1111/head.12835 10.1046/j.1526-4610.2001.111006171.x 10.1016/j.jemermed.2009.08.022 10.1016/j.annemergmed.2018.09.028 10.1177/0333102414566200 10.1097/AOG.0000000000004517 10.1111/head.12064 10.1111/bcpt.13579 10.1038/clpt.2008.157 10.1016/S0140-6736(06)69255-6 10.1016/j.ncl.2012.04.001 10.1016/j.ijoa.2006.08.015 10.1111/anae.12562 10.1136/rapm-2019-101053 10.1016/j.jclinane.2016.04.009 10.1111/head.13442 10.1016/j.ijoa.2016.10.010 10.1111/j.1399-6576.2010.02335.x 10.1097/AAP.0000000000000840 10.1016/j.jclinane.2014.03.006 10.1097/MD.0000000000028438 10.1016/j.ijoa.2018.12.006 10.1016/j.jocn.2017.02.046 10.1136/bcr-2013-009931 10.1016/j.ijoa.2021.103218 10.1097/AOG.0000000000002706 10.1097/AOG.0000000000002703 10.1097/01.AOG.0000423816.39542.0f 10.1001/jama.2021.7517 10.1136/practneurol-2016-001589 10.1155/2014/397131
Obstetrics and Gynecology;

May 17th, 2022 - To provide updated evidence-based recommendations for the evaluation and treatment of primary and secondary headaches in pregnancy and postpartum. Pregnant and postpartum patients with a history of or experiencing primary or new secondary headaches. This guideline was developed using an a priori protocol in conjunction with a writing team consisting of two specialists in obstetrics and gynecolo...

ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clini...
https://doi.org/10.1016/j.jacr.2022.02.015
Journal of the American College of Radiology : JACR; , Purysko AS et. al.

May 14th, 2022 - Renal cell carcinoma (RCC) accounts for most malignant renal tumors and is considered the most lethal of all urologic cancers. For follow-up of patients with treated or untreated RCC and those with neoplasms suspected to represent RCC, radiologic imaging is the most valuable component of surveillance, as most relapses and cases of disease progression are identified when patients are asymptomati...

ACR Appropriateness Criteria® Imaging of the Axilla.
https://doi.org/10.1016/j.jacr.2022.02.010
Journal of the American College of Radiology : JACR; , Le-Petross HT et. al.

May 14th, 2022 - This publication reviews the current evidence supporting the imaging approach of the axilla in various scenarios with broad differential diagnosis ranging from inflammatory to malignant etiologies. Controversies on the management of axillary adenopathy results in disagreement on the appropriate axillary imaging tests. Ultrasound is often the appropriate initial imaging test in several clinical ...

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radi...
https://doi.org/10.1097/JU.0000000000002759
The Journal of Urology; Eastham JA, Auffenberg GB et. al.

May 11th, 2022 - The summary presented herein represents Part III of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of radiation and offering several future directions of further relevant study in patients diagnosed with clinically localized prostate cancer. Please refer to Parts I and II for discussion of risk assessment, staging, and risk-ba...

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Activ...
https://doi.org/10.1097/JU.0000000000002758
The Journal of Urology; Eastham JA, Auffenberg GB et. al.

May 11th, 2022 - The summary presented herein represents Part II of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of active surveillance and surgery as well as follow-up for patients after primary treatment. Please refer to Parts I and III for discussion of risk assessment, staging, and risk-based management (Part I), and principles of radiat...

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk A...
https://doi.org/10.1097/JU.0000000000002757
The Journal of Urology; Eastham JA, Auffenberg GB et. al.

May 11th, 2022 - The summary presented herein represents Part I of the three-part series dedicated to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment, staging, and risk-based management in patients diagnosed with clinically localized prostate cancer. Please refer to Parts II and III for discussion of principles of active surveillance, surgery and follow-up (Part II), and pr...

Radiation Therapy for Brain Metastases: An ASTRO Clinical Practice Guideline.
https://doi.org/10.1016/j.prro.2022.02.003
Practical Radiation Oncology; Gondi V, Bauman G et. al.

May 10th, 2022 - This guideline provides updated evidence-based recommendations addressing recent developments in the management of patients with brain metastases, including advanced radiation therapy techniques such as stereotactic radiosurgery (SRS) and hippocampal avoidance whole brain radiation therapy and the emergence of systemic therapies with central nervous system activity. The American Society for Rad...

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
https://doi.org/10.1097/RLU.0000000000004182
Clinical Nuclear Medicine; Love C, Desai NB et. al.

May 5th, 2022 - This practice parameter (PP) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT) aims to guide authorized users in selection of appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETs) from foregut, midgut, and hindgut. The essential selection criteria include somatostatin receptor-positive GEP-NETs, which are usually inoperable and pr...

ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
https://doi.org/10.1097/COC.0000000000000903
American Journal of Clinical Oncology; Love C, Desai NB et. al.

May 5th, 2022 - This practice parameter (PP) for Lutetium-177 (Lu-177) DOTATATE peptide receptor radionuclide therapy (PRRT) aims to guide authorized users in selection of appropriate adult candidates with gastroeneropancreatic neuroendocrine tumors (GEP-NETs) from foregut, midgut, and hindgut. The essential selection criteria include somatostatin receptor-positive GEP-NETs, which are usually inoperable and pr...

2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in ...
https://doi.org/10.1016/j.hrthm.2022.04.022
Heart Rhythm; Groh WJ, Bhakta D et. al.

May 3rd, 2022 - This international multidisciplinary document is intended to guide electrophysiologists, cardiologists, other clinicians, and health care professionals in caring for patients with arrhythmic complications of neuromuscular disorders (NMDs). The document presents an overview of arrhythmias in NMDs followed by detailed sections on specific disorders: Duchenne muscular dystrophy, Becker muscular dy...

ACR-ABS-ASTRO Practice Parameter for the Performance of Low-Dose-Rate Brachytherapy.
https://doi.org/10.1097/COC.0000000000000912
American Journal of Clinical Oncology; Woodhouse KD, Devlin PM et. al.

Apr 30th, 2022 - The American College of Radiology (ACR), the American Brachytherapy Society (ABS), and the American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for the performance of low-dose-rate (LDR) brachytherapy. LDR brachytherapy is the application of radioactive sources in or on tumors in a clinical setting with therapeutic intent. The advantages of LDR...

Guidelines for Mobile Laboratories for Molecular Diagnostic Testing of COVID-19.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057824
Annals of Laboratory Medicine; Roh KH, Hong KH et. al.

Apr 27th, 2022 - With the rapid spread of the coronavirus disease (COVID-19), the need for rapid testing and diagnosis and consequently, the demand for mobile laboratories have increased. Despite this need, there are no clear guidelines for the operation, maintenance, or quality control of mobile laboratories. We provide guidelines for the operation, management, and quality control of mobile laboratories, and s...

Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: A...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029123
Current Oncology (Toronto, Ont.); Blanchette P, Sivajohanathan D et. al.

Apr 22nd, 2022 - The purpose of this guideline is to determine the clinical utility of multigene profiling assays in individuals with early-stage invasive breast cancer. This guideline was developed by Ontario Health (Cancer Care Ontario)'s Program in Evidence-Based Care (PEBC) through a systematic review of relevant literature, patient- and caregiver-specific consultation and internal and external reviews. Rec...

Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Pro...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019936
Orphanet Journal of Rare Diseases; Mosbah H, Donadille B et. al.

Apr 21st, 2022 - Dunnigan syndrome, or Familial Partial Lipodystrophy type 2 (FPLD2; ORPHA 2348), is a rare autosomal dominant disorder due to pathogenic variants of the LMNA gene. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins), is to provide health professionals with a guide to optimal management and care of patients with FPLD2, based on a ...

AGA Clinical Practice Update on the Role of Diet in Irritable Bowel Syndrome: Expert Re...
https://doi.org/10.1053/j.gastro.2021.12.248
Gastroenterology Chey WD, Hashash JG et. al.

Mar 27th, 2022 - Irritable bowel syndrome (IBS) is a commonly diagnosed gastrointestinal disorder that can have a substantial impact on quality of life. Most patients with IBS associate their gastrointestinal symptoms with eating food. Mounting evidence supports dietary modifications, such as the low-fermentable oligo-, di-, and monosaccharides and polyols (FODMAP) diet, as a primary treatment for IBS symptoms....

Quality and Safety Considerations in Stereotactic Radiosurgery and Stereotactic Body Ra...
https://doi.org/10.1016/j.prro.2022.03.001
Practical Radiation Oncology; Das IJ, Dawes SL et. al.

Mar 15th, 2022 - This updated report on stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) is part of a series of consensus-based white papers previously published addressing patient safety. Since the first white papers were published, SRS and SBRT technology and procedures have progressed significantly such that these procedures are now more commonly used. The complexity and submill...

An Evidence-Based Guideline for Surveillance of Patients after Curative Treatment for C...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870404
Current Oncology (Toronto, Ont.); Kennedy E, Zwaal C et. al.

Feb 25th, 2022 - To provide recommendations for a surveillance regimen that leads to the largest overall survival benefit for patients after curative treatment for Stage I-IV colon and rectal cancer. Consistent with the Program in Evidence-Based Care's standard approach, guideline databases, i.e., MEDLINE, EMBASE, PubMed, Cochrane Library, and PROSPERO, were systematically searched. Then, we drafted recommendat...